Skip to main content

Peer Review reports

From: Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial

Original Submission
12 Sep 2022 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
19 Oct 2022 Reviewed Reviewer Report
15 Nov 2022 Reviewed Reviewer Report
5 Dec 2022 Author responded Author comments - Shu Wang
Resubmission - Version 3
5 Dec 2022 Submitted Manuscript version 3
Publishing
12 Dec 2022 Editorially accepted
28 Dec 2022 Article published 10.1186/s12885-022-10439-0

You can find further information about peer review here.

Back to article page